A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active Rheumatoid Arthritis Failing Treatment With Methotrexate and TNF-alpha Blocking Agents
Latest Information Update: 02 May 2023
At a glance
- Drugs Zanolimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Emergent BioSolutions; Genmab
- 26 Apr 2023 According to ClinicalTrials.gov record, protocol has been amended to increase actual patient number from 75 to 83. New Primary endpoints has been added and trial focus also got changed to TU and AR.
- 06 Dec 2012 Primary endpoint addedd as reported by ClinicalTrials.gov.
- 14 Sep 2012 New trial record